Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

By W. Sandborn, C. Su, J. Panés. New England Journal of Medicine, 2017

699 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/4a283d70ec5d671a48f4978895f3fdfe8228b3fc

Citations in the corpus

• 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (2019, neutral): “Interleukin-17 (IL-17) inhibitors have not been shown to be efficacious in IBD, although tofacitinib is an approved treatment for ulcerative colitis (26,27).”